Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208002 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL7305261 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL8055345 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL8053046 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL13040191 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL16053956 | 0.95 | SPHK1 (0.50) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL15318844 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1068504 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1068506 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL16071281 | 0.89 | SPHK1 (0.58) | SPHK1HSD11B2BRD4NR1H2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4580639-A1 | TREATMENT OF FAMILIAL ADENOMATOUS POLYOPSIS USING A 13-MEMBERED MACROLIDE | Zikani Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-120152721-A | Treatment of familial adenomatous polyposis with 13-membered macrolides | 齐卡尼治疗股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025043115-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | ZIKANI THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024049994-A1 | TREATMENT OF FAMILIAL ADENOMATOUS POLYOPSIS USING A 13-MEMBERED MACROLIDE | ZIKANI THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2022251730-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2685982-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012125887-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2011092611-A1 | AMINOCYCLOHEXANES AND AMINOTETRAHYDROPYRANS AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-1532137-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014893-A2 | ANTIMICROBIAL AZA-BICYCLIC DERIVATES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | UPF1, RRP1B, REV1 | SPHK1 4627/4885HSD11B2 1889/4885BRD4 2434/4885 |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | SPHK1 2303/4885HSD11B2 1455/4885BRD4 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.